长链非编码 RNA LUCAT1 的高表达与实体瘤的不良临床结局相关：系统评价和荟萃分析。

High expression of long noncoding RNA LUCAT1 correlates with a poor clinical outcome in solid tumors: A systematic review and meta-analysis.

机构信息

Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China; Hubei Institute of Urology, Wuhan, 430030, China.

出版信息

Pathol Res Pract. 2020 Sep;216(9):153047. doi: 10.1016/j.prp.2020.153047. Epub 2020 Jun 4.

DOI:10.1016/j.prp.2020.153047

PMID:32825932

Abstract

BACKGROUNDS

Extensive studies have been performed to analyze the expression of long non-coding RNA the lung cancer associated transcript 1 (lncRNA LUCAT1) in various cancer types, and the predictive value of high or low lncRNA LUCAT1 level in survival time. We prepared to assess the association between the lncRNA LUCAT1 expression and the prognosis as well as clinical parameters in human cancers.

METHODS

We retrieved completely in some main databases, such as PubMed, Embase, Web of Science, China National Knowledge Internet (CNKI), and Wanfang database. Then we counted the pooled hazard ratio (HR) and odds ratio (OR) with 95 % confidence interval (CI) to investigate the clinical value of lncRNA LUCAT1.

RESULTS

We found that overexpression of lncRNA LUCAT1 was highly associated with shorter overall survival (HR = 1.91, 95 % CI: 1.59-2.31, P < 0.00001) through comprehensively analyzing eight of the total eleven eligible papers. Meanwhile, high lncRNA LUCAT1 expression was significantly related to deeper invasion depth (HR = 3.16, 95 % CI: 1.76-5.70, P = 0.0001), larger tumor size (HR = 2.10, 95 % CI: 1.54-2.86, P < 0.00001), advanced clinical stage (HR = 3.52, 95 % CI: 1.98-6.27, P < 0.0001), and more lymph node metastasis (HR = 2.99, 95 % CI: 1.36-6.57, P = 0.006), respectively.

CONCLUSIONS

Our outcomes suggest that upregulation of lncRNA LUCAT1 in patients with different cancers can predict a shorter survival time and act as an unfavorable prognostic molecular indicator.

摘要

背景

大量研究已经分析了长非编码 RNA 肺癌相关转录物 1（lncRNA LUCAT1）在各种癌症类型中的表达，以及高或低 lncRNA LUCAT1 水平对生存时间的预测价值。我们准备评估 lncRNA LUCAT1 表达与人类癌症的预后和临床参数之间的关系。

方法

我们在 PubMed、Embase、Web of Science、中国国家知识基础设施（CNKI）和万方数据库等主要数据库中进行了全面检索。然后，我们计算了合并的风险比（HR）和优势比（OR）及其 95%置信区间（CI），以研究 lncRNA LUCAT1 的临床价值。

结果

通过综合分析 11 篇合格文献中的 8 篇，我们发现 lncRNA LUCAT1 的过表达与总生存期更短密切相关（HR=1.91，95%CI：1.59-2.31，P<0.00001）。同时，lncRNA LUCAT1 的高表达与更深的浸润深度（HR=3.16，95%CI：1.76-5.70，P=0.0001）、更大的肿瘤大小（HR=2.10，95%CI：1.54-2.86，P<0.00001）、较晚的临床分期（HR=3.52，95%CI：1.98-6.27，P<0.0001）和更多的淋巴结转移（HR=2.99，95%CI：1.36-6.57，P=0.006）显著相关。